Operating Income: The income after operating expenses.
Xilio Therapeutics, Inc. (XLO) had Operating Income of $-41.98M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$43.77M |
|
$-35.04M |
|
-- |
|
$43.77M |
|
$85.75M |
|
|
Operating Income |
$-41.98M |
$6.95M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
$-35.04M |
|
$-41.98M |
|
$-40.44M |
|
8.36M |
|
8.36M |
|
$-4.19 |
|
$-4.19 |
|
| Balance Sheet Financials | |
$145.03M |
|
$3.89M |
|
$9.66M |
|
$154.69M |
|
$56.27M |
|
-- |
|
$63.14M |
|
$119.41M |
|
$35.27M |
|
$35.27M |
|
$35.27M |
|
4.53M |
|
| Cash Flow Statement Financials | |
$-4.99M |
|
$-0.52M |
|
$87.78M |
|
$57.07M |
|
$139.34M |
|
$82.27M |
|
$6.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-95.92% |
|
-95.92% |
|
-92.40% |
|
-80.05% |
|
-80.05% |
|
$-5.51M |
|
-- |
|
-- |
|
-- |
|
0.28 |
|
-- |
|
8.75 |
|
41.70 |
|
-99.33% |
|
-99.33% |
|
-22.65% |
|
-99.33% |
|
$7.78 |
|
$-0.66 |
|
$-0.60 |
|